Israel - English - Ministry of Health

taro international ltd, israel - dasatinib - film coated tablets - dasatinib 100 mg - dasatinib - dasatinib taro is indicated for the treatment of adult patients with: * newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. * chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate. * ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.

Israel - English - Ministry of Health

taro international ltd, israel - dasatinib - film coated tablets - dasatinib 140 mg - dasatinib - dasatinib taro is indicated for the treatment of adult patients with: * newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. * chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate. * ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.

Israel - English - Ministry of Health

taro international ltd, israel - dasatinib - film coated tablets - dasatinib 20 mg - dasatinib - dasatinib taro is indicated for the treatment of adult patients with: * newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. * chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate. * ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.

Israel - English - Ministry of Health

taro international ltd, israel - dasatinib - film coated tablets - dasatinib 50 mg - dasatinib - dasatinib taro is indicated for the treatment of adult patients with: * newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. * chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate. * ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.

Israel - English - Ministry of Health

taro international ltd, israel - dasatinib - film coated tablets - dasatinib 70 mg - dasatinib - dasatinib taro is indicated for the treatment of adult patients with: * newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. * chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate. * ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.

Israel - English - Ministry of Health

taro international ltd, israel - dasatinib - film coated tablets - dasatinib 80 mg - dasatinib - dasatinib taro is indicated for the treatment of adult patients with:* newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. * chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate. * ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.

United States - English - NLM (National Library of Medicine)

greenstone llc - sulfasalazine (unii: 3xc8guz6cb) (sulfasalazine - unii:3xc8guz6cb) - sulfasalazine 500 mg - sulfasalazine tablets are indicated: sulfasalazine tablets are contraindicated in: none reported.

United States - English - NLM (National Library of Medicine)

par pharmaceutical - sulfasalazine (unii: 3xc8guz6cb) (sulfasalazine - unii:3xc8guz6cb) - sulfasalazine 500 mg - sulfasalazine tablets, usp are indicated: - in the treatment of mild to moderate ulcerative colitis, and as adjunctive therapy in severe ulcerative colitis; and - for the prolongation of the remission period between acute attacks of ulcerative colitis. sulfasalazine tablets are contraindicated in: -  patients with intestinal or urinary obstruction, -  patients with porphyria as sulfonamides have been reported to precipitate an acute attack, -  patients hypersensitive to sulfasalazine, its metabolites, sulfonamides, or salicylates. none reported.

United States - English - NLM (National Library of Medicine)

greenstone llc - sulfasalazine (unii: 3xc8guz6cb) (sulfasalazine - unii:3xc8guz6cb) - sulfasalazine 500 mg - sulfasalazine delayed release tablets are indicated: sulfasalazine delayed release tablets are particularly indicated in patients with ulcerative colitis who cannot take uncoated sulfasalazine tablets because of gastrointestinal intolerance, and in whom there is evidence that this intolerance is not primarily the result of high blood levels of sulfapyridine and its metabolites, e.g., patients experiencing nausea and vomiting with the first few doses of the drug, or patients in whom a reduction in dosage does not alleviate the adverse gastrointestinal effects. in patients with rheumatoid arthritis or juvenile rheumatoid arthritis, rest and physiotherapy as indicated should be continued. unlike anti-inflammatory drugs, sulfasalazine delayed release tablets do not produce an immediate response. concurrent treatment with analgesics and/or nonsteroidal anti-inflammatory drugs is recommended at least until the effect of sulfasalazine delayed release tablets is apparent. sulfasalazine delayed release tablets are con

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - sulfasalazine (unii: 3xc8guz6cb) (sulfasalazine - unii:3xc8guz6cb) - sulfasalazine 500 mg - sulfasalazine tablets are indicated: a) in the treatment of mild to moderate ulcerative colitis, and as adjunctive therapy in severe ulcerative colitis; and b) for the prolongation of the remission period between acute attacks of ulcerative colitis. sulfasalazine tablets are contraindicated in: patients with intestinal or urinary obstruction, patients with porphyria as sulfonamides have been reported to precipitate an acute attack, patients hypersensitive to sulfasalazine, its metabolites, sulfonamides, or salicylates. none reported.